Antigen-specific T Cells Against Lung Cancer
Shenzhen Geno-Immune Medical Institute
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 20
- sponsor
- Shenzhen Geno-Immune Medical Institute
- conditions
- Lung Cancer
- interventions
- BIOLOGICAL: Lung cancer-specific T cells
- start date
- 2027-06-01
- start date type
- ESTIMATED
- primary completion date
- 2029-12-31
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT03356808
- Published
- Nov 29, 2017
- Updated
- Aug 26, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT03356808
- Categories
- Lung Cancer
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials